Pharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the month of April:

By: Anurag Relan, Pharming Chief Medical Officer

Pharming Group N.V. presents its preliminary (unaudited) financial report for the three months and full year ended December 31, 2023.

A conversation with Sarah, mom to Tyler and Kaitlyn, who are living with a rare disease known as APDS

Pharming Group N.V. confirms it will report its preliminary (unaudited) fourth quarter and full year 2023 financial results, for the period ended December 31, on Thursday, March 14, 2024.

On February 11, Pharming celebrates the International Day of Women and Girls in Science, which was first declared by the United Nations in 2015 to promote the full and equal access to, and participation of, women and girls in Science, Technology, Engineering and Mathematics (STEM) fields. The day promotes the role of women in scientific fields, promoting those already successful in the field, and aims to inspire more women and girls to pursue careers in science.

Pharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the month of February:

Expect 10% growth in RUCONEST® revenue, significantly exceeding prior guidance Expect Joenja® revenues of approximately US$18 million with 81 patients on paid therapy at year end

There’s strength in the stories of people living with rare diseases.

Initial development in PIDs with immune dysregulation linked to PI3Kẟ signaling Phase 2 clinical trial initiation planned for 2Q 2024